Bladder cancer trials in Estonia

1 trial · From EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

• Phase 4Taking people
  A Rollover Study to Follow the Long-term Durability of Response to UGN-103 in Participants With Recurrent Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer (LG-IR-NMIBC) From Study BL013

  Where

  Pohja-Tallinna Linnaosa, Tartu Linn

  Age

  18 years and over

  People

  33 worldwide

  Run by

  Urogen Pharma Ltd.

  See details and how to join2026-526359-75-00 · EU 2026-526359-75-00